20 growth stocks priced as value stocks

A screen identified 20 U.S. growth stocks trading at or below half the S&P 500's P/E valuation while also offering materially higher projected revenue growth through 2028. The list is concentrated in financial services (8 names), healthcare (5) and information technology (4), suggesting a value-oriented setup with growth characteristics. The article is largely a stock-screening exercise rather than a catalyst-driven news event, so near-term market impact is limited.

Analysis

This screen is less a “value” signal than a dispersion map: the market is still paying up for proven quality while underpricing the optionality embedded in slower-recognized earnings inflection stories. The second-order effect is that these names can re-rate violently on even modest evidence of execution, because low multiples leave little room for pessimism and sell-side models usually lag the first quarter of upward revisions. In practice, the winners are likely to be those with the cleanest path to near-term estimate revisions, not the highest long-dated growth rates.

The financials cluster is the most interesting because the market often treats them as ex-growth until something forces a re-underwrite. If these are balance-sheet-light, fee-driven, or capital-return-heavy franchises, they can screen cheap for a long time until buybacks or margin normalization compress the valuation gap. The risk is that some of the apparent “cheapness” is actually cyclicality or credit quality concern in disguise, which can look fine on forward revenue screens but break quickly if funding conditions tighten or underwriting assumptions move.

Healthcare and software-like IT names with low multiples and high growth projections are the clearest contrarian setup, but the catalyst horizon matters: these are usually 6-18 month stories, not next-quarter trades. The market is likely missing that once growth re-accelerates, the first move is often multiple expansion before fundamentals fully show up, creating a fast 20-30% rerate window. Conversely, if those estimates are too optimistic, the downside can be abrupt because consensus has already anchored on a benign glide path.

Net: this is a hunting list for long-biased special situations, but the right expression is selective and catalyst-driven rather than basket-wide. The best opportunities are names where the gap between current multiple and expected growth can close through a visible near-term event—earnings revision, guidance reset, capital return step-up, or regulatory clarity—while the worst traps are those whose cheapness is simply the market pricing in a deteriorating business model.

Key Decisions for Investors

• Build a selective long basket of the top 3-5 names with the highest ratio of projected growth to P/E compression potential; size initial positions at 50-75 bps each and require a first-quarter post-entry earnings confirmation before adding.
• Favor financial services names with recurring fee income and buyback capacity over credit-sensitive lenders; hold 3-6 months for re-rating potential, but cut quickly if net interest margin or reserve commentary deteriorates.
• Target healthcare names where pipeline/launch timing can drive estimate revisions within 1-2 quarters; use call spreads to capture a 20-30% rerate while limiting downside if development timelines slip.
• Avoid constructing a passive equal-weight basket; instead, short the weakest low-multiple/high-growth names as a hedge against estimate traps, especially where revenue growth depends on one or two assumptions that are easy to miss in consensus models.
• If one or two names gap up on earnings and guidance, rotate out of the basket winners into the laggards rather than pressing the winners immediately; the market often rewards the first positive surprise with a quick 15-25% move, but follow-through is typically lower.